269 related articles for article (PubMed ID: 23621771)
1. 5-Azacytidine for the treatment of myelodysplastic syndromes.
Krawczyk J; Keane N; Freeman CL; Swords R; O'Dwyer M; Giles FJ
Expert Opin Pharmacother; 2013 Jun; 14(9):1255-68. PubMed ID: 23621771
[TBL] [Abstract][Full Text] [Related]
2. 5-Azacytidine/Azacitidine.
Müller A; Florek M
Recent Results Cancer Res; 2010; 184():159-70. PubMed ID: 20072837
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
Santini V
Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone G; Teofili L; Voso MT; Lübbert M
Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
[TBL] [Abstract][Full Text] [Related]
5. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
6. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
Itzykson R; Fenaux P
Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
8. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
Silverman LR; Mufti GJ
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
[TBL] [Abstract][Full Text] [Related]
9. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
10. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
[TBL] [Abstract][Full Text] [Related]
11. Use of hypomethylating agents in myelodysplastic syndromes.
Atallah E; Garcia-Manero G
Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment.
Douvali E; Papoutselis M; Vassilakopoulos TP; Papadopoulos V; Spanoudakis E; Tsatalas C; Kotsianidis I
Leuk Res; 2013 Aug; 37(8):889-93. PubMed ID: 23726719
[TBL] [Abstract][Full Text] [Related]
13. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
Demakos EP; Linebaugh JA
Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
[TBL] [Abstract][Full Text] [Related]
14. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
Kuykendall JR
Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
[TBL] [Abstract][Full Text] [Related]
15. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
Scott LJ
Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine for the treatment of myelodysplastic syndrome.
Cataldo VD; Cortes J; Quintás-Cardama A
Expert Rev Anticancer Ther; 2009 Jul; 9(7):875-84. PubMed ID: 19589026
[TBL] [Abstract][Full Text] [Related]
17. Decitabine.
Gore SD; Jones C; Kirkpatrick P
Nat Rev Drug Discov; 2006 Nov; 5(11):891-2. PubMed ID: 17117522
[No Abstract] [Full Text] [Related]
18. Azacitidine.
Issa JP; Kantarjian HM; Kirkpatrick P
Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
[No Abstract] [Full Text] [Related]
19. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
[TBL] [Abstract][Full Text] [Related]
20. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Fenaux P; Ades L
Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
